Craig Gibbs

Craig Gibbs serves as the Chief Executive Officer, bringing over three decades of experience in the biopharmaceutical sector. He has played a pivotal role in the development, launch, and commercialization of 12 FDA-approved drugs. Previously, Gibbs was the Chief Business Officer at Forty Seven Inc. and spent 21 years at Gilead Sciences where he held various leadership roles, including Vice President of Commercial Strategy. He is actively involved in the industry and academia, serving on the Boards of Directors for Aridis Pharmaceuticals, Inipharm Inc., and the Northern California Chapter of the Leukemia and Lymphoma Society. Gibbs was a postdoctoral fellow in the Protein Engineering Department at Genentech, where he began his distinguished career in science. He has published over 50 scientific articles and holds three issued patents. Gibbs received his Ph.D. in Molecular Biology from the University of Glasgow, Scotland, and holds a B.Sc. (Hons) in Biochemistry from Massey University, New Zealand. Additionally, he earned an M.B.A. from Golden Gate University in San Francisco, CA.